AST SpaceMobile stock price jumps 9% as traders refocus on BlueBird 7 launch timeline
28 January 2026
2 mins read

AST SpaceMobile stock price jumps 9% as traders refocus on BlueBird 7 launch timeline

New York, January 28, 2026, 15:18 EST — During the regular session

  • AST SpaceMobile shares jumped in afternoon trading following a choppy start to the week.
  • Investors are focused on the upcoming satellite launch as the company advances its 2026 target for “direct-to-device” service.
  • Execution risk remains a key concern, as skeptics doubt whether the launch pace can be maintained.

Shares of AST SpaceMobile climbed roughly 9% to $121.42 in afternoon trading Wednesday, after earlier fluctuating between $111.65 and $124.02. The move happened on robust volume, nearing 13 million shares traded.

The next few weeks are crucial for the company’s rollout plan. Investors want to see if AST can stick to its launch schedule and convert early satellite deployments into functioning coverage instead of just isolated demos.

AST is developing a “direct-to-device” network—satellite connections compatible with regular smartphones—designed to push mobile coverage past traditional cell tower limits. The concept sounds straightforward. The execution, far from it.

This week, AST reminded partners and shareholders of its near-term goals: a BlueBird 7 satellite launch slated for late February and a broad plan to roll out commercial service in 2026. The company noted these next-gen satellites feature a communications array covering roughly 2,400 square feet and can hit peak data speeds of 120 Mbps. Launches are expected every one to two months throughout 2026 as AST aims to deploy between 45 and 60 satellites by year-end. Scott Wisniewski, AST’s President and Chief Strategy Officer, described the BlueBird 7 launch as a key step forward in the push toward commercial service. 1

That timeline alone has drawn buyers back in—at least for the moment—after volatile day-to-day swings turned ASTS into as much a trader’s play as a telecom rollout story.

There’s a clear risk: timelines slip, launches cluster, or capacity proves tougher to lock down than investors anticipate. Satellite analyst Tim Farrar, president of TMF Associates, warned AST’s plans for early 2026 launches and hitting 45–60 satellites by year-end “are not happening.” He points out the numbers don’t add up if launches slow or carry fewer satellites than expected. Novaspace consultant Sumaiya Najarali described the target as “definitely ambitious,” noting the first quarter’s results will be key to gauging what 2026 holds. The competition is heating up too, with SpaceX’s Starlink ramping up direct-to-device services alongside U.S. carriers. 2

That uncertainty works both ways for investors. If AST meets the cadence, it bolsters the argument that service could shift from “intermittent” to more continuous coverage down the line. But if it falls short, the stock could swiftly reprice, since the whole story hinges on execution.

On the Street, the focus is sharpening on how many satellites are needed to deliver a service customers will actually want. After recent talks with the company, William Blair stuck to a Market Perform rating, suggesting around 25 satellites might provide intermittent coverage in key markets for now. More extensive service is anticipated as the constellation expands through 2026. 3

Traders are focused on one key point: whether the late-February window for BlueBird 7 holds firm. They’re also looking for hints that subsequent launches are lining up behind it. Any updates from carrier partners about trial schedules would help clarify when revenue might start flowing.

AST is set to update investors next with its quarterly earnings, penciled in for around March 2 on most market calendars. Details on launch schedules, satellite production rates, and cash requirements could push the stock up or down ahead of the late-February launch window. 4

Stock Market Today

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
New York, Feb 7, 2026, 09:35 EST — Market closed. Roivant Sciences Ltd shares leapt on Friday after the company reported positive mid-stage results for its immune-modulating drug brepocitinib in a rare skin disease, and paired the readout with its quarterly financial update. The Nasdaq-listed stock closed up 22.4% at $25.82, leaving traders to gauge whether the move has legs when U.S. markets reopen on Monday, Feb. 9. It matters because Roivant is trying to turn a late-stage pipeline into approvals, and the market has been quick to reward biotechs that can show clean efficacy in controlled trials. The company
Amazon stock tumbles on $200 billion AI spend plan — what to know before Monday

Amazon stock tumbles on $200 billion AI spend plan — what to know before Monday

7 February 2026
Amazon shares fell 5.6% to $210.32 on Friday after the company projected about $200 billion in 2026 capital expenditures, triggering investor concern over AI spending. The stock had already dropped 11.5% after-hours Thursday. Amazon forecast Q1 net sales of $173.5–$178.5 billion and operating income of $16.5–$21.5 billion. Analyst Gil Luria downgraded Amazon, citing rising investment as its cloud lead narrows.
AMD stock jumps 8% in chip rebound — what investors are watching before Monday

AMD stock jumps 8% in chip rebound — what investors are watching before Monday

7 February 2026
AMD shares jumped 8.2% to $208.44 Friday, trading on heavy volume as chip stocks rebounded and the Dow closed above 50,000 for the first time. The Philadelphia Semiconductor Index rose 5.7% after Amazon’s AI spending plans lifted sector estimates. Nvidia’s CEO cited surging AI chip demand. AMD’s rally followed a weak revenue outlook earlier in the week.
Gilead stock dips as Medicare targets Biktarvy for 2028 price talks — and Trodelvy gets a guideline lift
Previous Story

Gilead stock dips as Medicare targets Biktarvy for 2028 price talks — and Trodelvy gets a guideline lift

Reddit stock slips again as ad-growth worries linger ahead of Feb. 5 earnings
Next Story

Reddit stock slips again as ad-growth worries linger ahead of Feb. 5 earnings

Go toTop